Can you take Tildrakizumab with Ublituximab?

Tildrakizumab has a major potential interaction with History, Tuberculosis.

Do not administer tildrakizumab to patients with active TB infection. It is recommended to assess patients for tuberculosis (TB) infection before starting treatment with this agent. Consider anti-TB therapy prior to initiation of tildrakizumab in patients with latent TB, a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after treatment with tildrakizumab.

Ublituximab has a moderate potential interaction with Immunodeficiency.

Ublituximab has been associated with serious, including life-threatening or fatal, bacterial and viral infections. Delay treatment in patients with active infection until resolution. Monitor the levels of quantitative serum immunoglobulins during treatment, especially in patients with opportunistic or recurrent infections, and after discontinuation of therapy until B-cell repletion. For patients with low serum immunoglobulins, consult immunology experts before initiating therapy. Consider treatment discontinuation if a patient with low immunoglobulins develops a serious opportunistic infection or recurrent infections, or if prolonged hypogammaglobulinemia requires therapy with IV immunoglobulins.

Tildrakizumab has a moderate potential interaction with Infection.

The use of tildrakizumab may increase the risk of infection. Treatment with tildrakizumab should not be started in patients with active infection until the infection resolves or is adequately treated. Consider the risks and benefits prior to using this agent in patients with chronic infection or a history of recurrent infection. It is recommended to monitor the patient closely and consider discontinuation of tildrakizumab if a patient develops a clinically important or serious infection or is not responding to standard therapy.

Ublituximab has a moderate potential interaction with Infection.

Ublituximab has been associated with serious, including life-threatening or fatal, bacterial and viral infections. Delay treatment in patients with active infection until resolution. Monitor the levels of quantitative serum immunoglobulins during treatment, especially in patients with opportunistic or recurrent infections, and after discontinuation of therapy until B-cell repletion. For patients with low serum immunoglobulins, consult immunology experts before initiating therapy. Consider treatment discontinuation if a patient with low immunoglobulins develops a serious opportunistic infection or recurrent infections, or if prolonged hypogammaglobulinemia requires therapy with IV immunoglobulins.

Ublituximab has a major potential interaction with Infectious Hepatitis.

Use of ublituximab is contraindicated in patients with active hepatitis b virus (HBV) infection. Reactivation of HBV has been reported with use of ublituximab. Perform HBV screening in all patients prior to therapy. Consult a liver disease expert in patients who are negative for surface antigen (HBsAg) and positive for HB core antibody (HBcAb+), or are carriers of HBV (HBcAb+).

Ublituximab has a moderate potential interaction with Liver Disease.

Ublituximab may cause liver injury. Patients with ALT/AST greater than 3 times the upper limit of normal (3 x ULN) and total bilirubin greater than 2 x ULN are at risk for severe drug-induced liver injury. The effect of moderate to severe liver dysfunction on the pharmacokinetics of ublituximab is unknown. Prior to therapy with ublituximab, assess ALT, AST, alkaline phosphatase, and bilirubin levels. Monitor for signs and symptoms of any drug-induced liver injury during treatment; discontinue therapy if identified.

Ublituximab has a moderate potential interaction with Renal Dysfunction.

The effect of moderate to severe renal dysfunction on the pharmacokinetics of ublituximab is unknown.

Tildrakizumab has a major potential interaction with Tuberculosis, Active.

Do not administer tildrakizumab to patients with active TB infection. It is recommended to assess patients for tuberculosis (TB) infection before starting treatment with this agent. Consider anti-TB therapy prior to initiation of tildrakizumab in patients with latent TB, a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after treatment with tildrakizumab.

Tildrakizumab has a major potential interaction with Tuberculosis, Latent.

Do not administer tildrakizumab to patients with active TB infection. It is recommended to assess patients for tuberculosis (TB) infection before starting treatment with this agent. Consider anti-TB therapy prior to initiation of tildrakizumab in patients with latent TB, a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after treatment with tildrakizumab.

Tildrakizumab has a moderate potential interaction with Vaccination.

It is recommended to avoid the use of live vaccines in patients treated with tildrakizumab. Before starting therapy with tildrakizumab, consider completion of all age appropriate immunizations according to current immunization guidelines. Care should be exercised as no data are available on the response to live or inactive vaccines.